ORIENT-11: Sintilimab plus Pemetrexed plus Platinum as First-Line Therapy for Locally Advanced or Metastatic Non-Squamous NSCLC

被引：0
|
作者：
Zhang, L. [1 ]
Yang, Y. [1 ]
Wang, Z. [2 ]
Fang, J. [3 ]
Yu, Q. [4 ]
Han, B. [5 ]
Cang, S. [6 ]
Chen, G. [7 ]
Mei, X. [8 ]
Yang, Z. [9 ]
Ma, R. [10 ]
Bi, M. [11 ]
Ren, X. [12 ]
Zhou, J. [13 ]
Li, B. [14 ]
Xu, W. [15 ]
Ji, Y. [15 ]
Peng, B. [15 ]
机构：
[1] Sun Yat Sen Univ, Canc Ctr, Guangzhou, Peoples R China
[2] Shandong Prov Canc Hosp, Jinan, Peoples R China
[3] Peking Univ, Canc Hosp, Beijing, Peoples R China
[4] Tumor Hosp Guangxi Zhuang Autonomous Reg, Nanning, Peoples R China
[5] Shanghai Chest Hosp, Shanghai, Peoples R China
[6] Henan Prov Peoples Hosp, Zhengzhou, Peoples R China
[7] Harbin Med Univ, Canc Hosp, Harbin, Peoples R China
[8] Anhui Prov Hosp, Hefei, Peoples R China
[9] Guangdong Med Univ, Affiliated Hosp, Guangzhou, Peoples R China
[10] Liaoning Canc Hosp, Shenyang, Peoples R China
[11] Bengbu Med Coll, Affiliated Hosp 1, Bengbu, Peoples R China
[12] Tianjin Canc Inst & Hosp, Tianjin, Peoples R China
[13] Zhejiang Univ, Affiliated Hosp 1, Hangzhou, Peoples R China
[14] Capital Med Univ, Beijing Chest Hosp, Beijing, Peoples R China
[15] Innovent Biol Inc, Shanghai, Peoples R China
来源：
JOURNAL OF THORACIC ONCOLOGY | 2020年 / 15卷 / 10期
关键词：
anti-PD-1; antibody; chemotherapy; nsqNSCLC;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
ID:1329
引用
收藏
页码：E41 / E41
页数：1
相关论文
共 50 条
  • [21] Comparing the cost-effectiveness of sintilimab plus pemetrexed plus platinum and pemetrexed plus platinum alone as a first-line therapy for Chinese patients with nonsquamous non-small cell lung cancer
    Shi, Yafei
    Qian, Di
    Li, Yanhui
    Chen, Wei
    Bo, Mingming
    Zhang, Mingyu
    Shi, Jianglei
    Jia, Bei
    Dai, Yuanyuan
    Li, Guohui
    TRANSLATIONAL CANCER RESEARCH, 2023, 12 (04) : 928 - +
  • [22] PEMBROLIZUMAB PLUS CHEMOTHERAPY FOR FIRST-LINE TREATMENT OF METASTATIC NON-SQUAMOUS NSCLC - A NETWORK META-ANALYSIS
    Frederickson, A. M.
    Arndorfer, S.
    Lorenzi, M.
    Insinga, R.
    Chandwani, S.
    Burke, T.
    VALUE IN HEALTH, 2018, 21 : S20 - S20
  • [23] Pembrolizumab plus pemetrexed and platinum vs placebo plus pemetrexed and platinum as first-line therapy for metastatic nonsquamous NSCLC: analysis of KEYNOTE-189 by STK11 and KEAP1 status
    Gadgeel, Shirish M.
    Rodriguez-Abreu, Delvys
    Felip, Enriqueta
    Esteban, Emilio
    Speranza, Giovanna
    Reck, Martin
    Hui, Rina
    Boyer, Michael
    Garon, Edward B.
    Horinouchi, Hidehito
    Cristescu, Razvan
    Aurora-Garg, Deepti
    Loboda, Andrey
    Lunceford, Jared
    Kobie, Julie
    Ayers, Mark
    Piperdi, Bilal
    Pietanza, M. Catherine
    Garassino, Marina C.
    CANCER RESEARCH, 2020, 80 (16)
  • [24] Cost-effectiveness analysis of sintilimab plus chemotherapy versus camrelizumab plus chemotherapy for the treatment of first-line locally advanced or metastatic nonsquamous NSCLC in China
    Rui, Mingjun
    Fei, Zhengyang
    Wang, Yingcheng
    Zhang, Xueke
    Ma, Aixia
    Sun, Haikui
    Li, Hongchao
    JOURNAL OF MEDICAL ECONOMICS, 2022, 25 (01) : 618 - 629
  • [25] Real-world outcomes of Italian patients with advanced non-squamous lung cancer treated with first-line pembrolizumab plus platinum-pemetrexed
    Leonetti, Alessandro
    Perrone, Fabiana
    Puntoni, Matteo
    Maglietta, Giuseppe
    Bordi, Paola
    Bria, Emilio
    Vita, Emanuele
    Gelsomino, Francesco
    De Giglio, Andrea
    Gelibter, Alain
    Siringo, Marco
    Mazzoni, Francesca
    Caliman, Enrico
    Genova, Carlo
    Bertolini, Federica
    Guaitoli, Giorgia
    Passiglia, Francesco
    Delcuratolo, Marco Donatello
    Montrone, Michele
    Cerea, Giulio
    Pasello, Giulia
    Roca, Elisa
    Belluomini, Lorenzo
    Cecere, Fabiana Letizia
    Guida, Annalisa
    Manzo, Anna
    Adamo, Vincenzo
    Rastelli, Francesca
    Bulotta, Alessandra
    Citarella, Fabrizio
    Toschi, Luca
    Zoratto, Federica
    Cortinovis, Diego Luigi
    Berardi, Rossana
    Follador, Alessandro
    Carta, Annamaria
    Camerini, Andrea
    Salerno, Flavio
    Silva, Rosa Rita
    Baldini, Editta
    Cortellini, Alessio
    Brighenti, Matteo
    Santoni, Matteo
    Malorgio, Francesco
    Caminiti, Caterina
    Tiseo, Marcello
    EUROPEAN JOURNAL OF CANCER, 2024, 202
  • [26] MHC-II antigen presentation pathway as a predictive biomarker for sintilimab plus chemotherapy in first-line treatment of locally advanced or metastatic non-squamous non-small cell lung cancer (nsq-NSCLC)
    Yang, Y.
    Sun, J.
    Wang, Z.
    Fang, J.
    Yu, Q.
    Han, B.
    Cang, S.
    Chen, G.
    Mei, X.
    Yang, Z.
    Ma, R.
    Bi, M.
    Ren, X.
    Zhou, J.
    Li, B.
    Zhou, H.
    Wang, S.
    Xu, W.
    Peng, B.
    Zhang, L.
    ANNALS OF ONCOLOGY, 2020, 31 : S1186 - S1186
  • [27] Pemetrexed plus Platinum Chemotherapy with or Without Immunotherapy in Non-Squamous NSCLC: Descriptive Safety Analysis
    Govindan, R.
    Borghaei, H.
    He, S.
    Kim, J. S.
    Papadimitrakopoulou, V.
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S2083 - S2084
  • [28] Efficacy and Safety of Sintilimab Plus Pemetrexed and Platinum as First-Line Treatment for Locally Advanced or Metastatic Nonsquamous NSCLC: a Randomized, Double-Blind, Phase 3 Study (Oncology pRogram by InnovENT anti-PD-1-11)
    Yang, Yunpeng
    Wang, Zhehai
    Fang, Jian
    Yu, Qitao
    Han, Baohui
    Cang, Shundong
    Chen, Gongyan
    Mei, Xiaodong
    Yang, Zhixiong
    Ma, Rui
    Bi, Minghong
    Ren, Xiubao
    Zhou, Jianying
    Li, Baolan
    Song, Yong
    Feng, Jifeng
    Li, Juan
    He, Zhiyong
    Zhou, Rui
    Li, Weimin
    Lu, You
    Wang, Yingyi
    Wang, Lijun
    Yang, Nong
    Zhang, Yan
    Yu, Zhuang
    Zhao, Yanqiu
    Xie, Conghua
    Cheng, Ying
    Zhou, Hui
    Wang, Shuyan
    Zhu, Donglei
    Zhang, Wen
    Zhang, Li
    JOURNAL OF THORACIC ONCOLOGY, 2020, 15 (10) : 1636 - 1646
  • [29] First-line Atezolizumab plus Bevacizumab for Metastatic High-Intermediate TMB in Non-squamous NSCLC. The TELMA Study
    Provencio-pulla, M.
    Ortega, A. L.
    Coves, J.
    Franco, F.
    Marse, R.
    Domine, M.
    Guirado, M.
    Carcereny, E.
    Fernandez, N.
    Martinez, E.
    Blanco, R.
    Leon, L.
    Sanchez, J. M.
    Sullivan, I.
    Cobo, M.
    Sanchez, A.
    Massuti, B.
    JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (09) : S123 - S124
  • [30] Sintilimab plus chemotherapy versus chemotherapy as first-line therapy in patients with advanced or metastatic esophageal squamous cell cancer: First results of the phase III ORIENT-15 study
    Shen, L.
    Lu, Z-H.
    Wang, J-Y.
    Shu, Y-Q.
    Kong, L.
    Yang, L.
    Wang, B-H.
    Wang, Z-W.
    Ji, Y-H.
    Cao, G-C.
    Liu, H.
    Cui, T-J.
    Li, N.
    Qiu, W-S.
    Ma, Z.
    Chen, Y-L.
    Li, H-Y.
    Sun, X.
    Wang, Y.
    Zhou, H.
    ANNALS OF ONCOLOGY, 2021, 32 : S1330 - S1330
12345